Every diabetic patient inquires hopefully about the possibilities of oral therapy. Good prospects for successful control of blood sugar can be held out to those whose diabetes developed after they were forty years of age, but for the patient who acquired detectable diabetes in childhood there is, with very rare exceptions, no prospect of benefit from tolbutamide.* Disappointing prospects may be less poignant if it is shown that because of tolbutamide and related substances, research in diabetes has reached an intensity never equalled in the past. Also, there is some comfort in knowing that preliminary reports on newer orally effective products indicate a favorable influence on hyperglycemia and glycosuria in some young patients. The truth about the inffectiveness of the sulfonylurea compounds is accepted with better grace if hope is not extinguished. These patients may not feel so disappointed when they learn that the oral preparations are a matter of convenience only and that they have no other known advantages, but rather several disadvantages over insulin therapy; that insulin after all is still the ideal agent as it corrects, physiologically, what they lack; that oral therapy holds no prospect whatever for a cure of the diabetes and does not decrease the need for attention to their diets nor to the testing for glycosuria; that insulin therapy must be resumed during acute complications, a procedure which may be more complicated than if one merely had to adjust one's dosage of insulin; and that if physicians specializing in the treatment of diabetic patients had a choice of only one drug, insulin or an oral preparation, the choice, because of the need for insulin when complications threaten life, would always be insulin.
For the "adult acquired" diabetes and especially in those patients over forty years of age, the physician's * Available commercially as Orinase (Upjohn). approach may be quite different from that outlined above. Instead of engendering undue optimism in these patients, the majority of whom will respond favorably to oral therapy, an attitude of caution is to be recommended. A "wait and see -and hope" attitude prepares patients for the disappointment should they, for one reason or another, be obliged to return to insulin therapy. The idea of a cure has been planted, without the slightest foundation, in the patient's mind by some articles in the press. This should be dispelled.
The patient is made aware that we are traveling an uncharted course and must be more alert than ever until the potentials, good or bad, of these drugs, as they affect the great variety of patients under a great variety of circumstances, are familiar to us.
Diabetics are usually better trained than other patients and they accept readily the need for daily communication with their physician for the first week or two of oral therapy if appreciable reductions in insulin, or its omission, have been adopted at the onset of oral therapy. They are instructed to test every specimen of urine, immediately after voiding, for sugar and acetone for at least four days after insulin has been greatly reduced or omitted. Persistent glycosuria means that the oral therapy will be inadequate, but the prompt appearance of acetone is a danger signal and demands the immediate return to insulin treatment. The occurrence of increasing ketonuria in the absence of an acute complication is, I believe, an indication that the individual is not a candidate for oral therapy.
Individualized instruction regarding unfavorable effects of oral therapy appears advisable. Side effects need not be elaborated upon if the patient is cooperative and can be relied upon to remain under close supervision and to report unusual symptoms. For the less reliable patient, some of the possible side effects, even though rare, are brought to his attention. This encourages cooperation in this early phase of a new treatment. It is well that all patients taking tolbutamide, or related agents, should know that they, as well as the doctor, are on a long-term pioneering project in therapy. The outlook is favorable but until the mode of action of these drugs is clearly understood, their long-term use is not devoid of apprehension nor should it be without caution.
Approximately 80 per cent of adult diabetics are overweight when they seek treatment. Two thirds, at least, of this large group are candidates for oral therapy and spectacular control of the glycosuria and hyperglycemia with tolbutamide may be expected. But, it is well to sensitize these patients to the fact that no oral therapy is a suitable substitute for an appropriate reduction in weight; that tolbutamide does not increase appetite, hence supplements well the benefits of a reducing regimen for the overweight patient; and that the need for drug therapy decreases and may disappear as the weight approaches the ideal. Knowingly to accept the advantages of tolbutamide and to ignore those of a temporarily reduced diet may be likened to the behavior of children who accept privileges but shun responsibilities.
The instruction of patients regarding oral therapy is for the most part an individualized affair but it is pertinent that all know some salient facts about tolbutamide :
a. It is effective in controlling the diabetes in the majority of the older and is rarely effective in young diabetics or in those who acquired diabetes while they were young.
b. It is not a form of insulin nor does it act like insulin.
c. It is not a cure for diabetes. d. When the diabetes may be controlled by diet alone, the drug is unnecessary.
e. It is ineffective during acute complications, notably acute infections, surgical procedures and ketosis.
f. Its favorable effect is transitory (four to six months) in some patients.
g. It does not reduce the need for attention to diet, tests for sugar and acetone in the urine. These measures are of special importance in the first few days of oral therapy.
h. There are no advantages except in rare instances in using insulin and tolbutamide simultaneously. i. Unlike the great variety of doses of insulin, the dosage of tolbutamide is relatively uniform, preferably at i.o or 1.5 gm. and not more than 2 gm. daily given in divided doses for long-term treatment.
j. The dosage of tolbutamide is changed only under the physician's direction. Excessive amounts have been known to increase the level of the blood sugar, the degree of glycosuria and the incidence of unfavorable side effects.
k. The change from insulin to oral therapy is accomplished by different plans according to the severity of the diabetes and the likelihood of a favorable response. For some, indeed for the majority, this can be accomplished on an outpatient basis. For others, hospitalization is highly desirable.
1. Hypoglycemic reactions are most likely to occur during the transition period from insulin to tolbutamide. Such reactions are rare with tolbutamide alone but when they do occur, the symptoms are identical to those of a hypoglycemia due to insulin. The treatment in both cases is the same. m. Studies, in addition to blood sugar determinations and urinalyses, should be done at frequent intervals until it is certain that the new drug is well tolerated by the patient. These studies will include especially blood counts and the checking of the function of the liver.
n. Research workers and physicians have zealously guarded the welfare of diabetic patients in the development of oral therapy and this keen acceptance of responsibility has been shared by the pharmaceutical firms interested in these new agents.
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OCULAR NERVE PALSY IN DIABETES
Attention has been called recently to the frequency of ocular nerve palsy associated with severe headache occurring in diabetic patients.
-
2 This syndrome of ocular nerve palsy associated with headache has been recognized for a long time. It is a rather frequent disorder, particularly when the paralysis is that of the oculomotor nerve. It usually comes on suddenly and is accompanied by severe pain on the same side of the head. Most of the patients who show this disease also demonstrate hemorrhages and exudates in the fundus as well as evidences of vascular disease in the retinal vessels. Dieulafoy 3 in 1905 collected several cases of extraocular muscle paralysis due to diabetes mellitus. The association of such paralyses with diabetes mellitus has been noted in large series of patients by several investigators.
Recovery is the rule in these cases. Waind 2 has noted that this is one of the most important features of this syndrome. Speculation has been made concerning the etiology and exact nature of the lesion. It is suggested that it is of vascular origin, perhaps a minute hemorrhage either into the nerve trunk or about the nucleus of the oculomotor nerve. This theory is supported by the rapidity of onset in a great majority of cases with complete paralysis of the nerves involved. The tendency toward total regression has been mentioned, although recovery of function may require several months. Vitamin deficiencies frequently noted in diabetes mellitus and polyneuritis have also been suggested as causes of the ocular palsies. 6 -8 A recent pathohistologic observation has been made in diabetic oculomotor palsy by
